Sanofi announced the appointment of Muzammil “Muz” Mansuri as a new member of the Executive Committee, effective February 22, 2016. Mansuri joins Sanofi from Gilead Sciences and will take the position of executive vice president, strategy & business development.
Mansuri will be responsible for all Group strategic planning, business development, strategic intelligence, alliance management and the Sanofi Genzyme Bio Ventures fund.
“Muz brings a wealth of experience as a senior executive within the global biopharmaceutical industry,” said Olivier Brandicourt, CEO, Sanofi. “Muz’s deep understanding of business development and strategy of global biopharmaceutical organisations will allow him to contribute significantly to the overall Group strategy and make him a valuable addition to Sanofi and the Executive Committee.”
A dual citizen of the US and United Kingdom, Mansuri has more than 35 years of experience beginning in 1981 with Shell Research Limited where he began as a research scientist. After Shell, he spent several years with Bristol-Myers Company in various R&D roles with increasing responsibility. From 2007 to 2010, Mansuri was chairman and CEO at CGI Pharmaceuticals. Mansuri’s most recently was senior vice president, research & development strategy and corporate development at Gilead Sciences.
Mansuri holds a bachelor of science degree in chemistry and a Ph.D in organic chemistry from the University College London. He held post-doctoral positions at the University of California, Los Angeles (UCLA) and Columbia University.
Source: pharmabiz
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
